Tidlira (Tirzepatide) 30mg Pen - UPA
Tirzepatide, also known by its development code Mounjaro, is a novel investigational medication designed to address the complex challenges of type 2 diabetes mellitus (T2DM). Developed by Eli Lilly and Company, tirzepatide represents an innovative approach to diabetes management, belonging to a class of drugs known as dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists.
In the body, both GIP and GLP-1 are hormones that play crucial roles in regulating blood sugar levels and metabolism. GIP is secreted by the gut in response to nutrient intake and stimulates insulin secretion from pancreatic beta cells. GLP-1 is also released from the gut and acts on pancreatic beta cells to stimulate insulin secretion while simultaneously inhibiting glucagon release, slowing gastric emptying, and promoting satiety. By targeting both of these pathways simultaneously, tirzepatide offers a multifaceted approach to glycemic control in individuals with T2DM.
Tirzepatide works by activating GIP and GLP-1 receptors, leading to increased insulin secretion, decreased glucagon release, slowed gastric emptying, and reduced food intake. This comprehensive mechanism of action makes tirzepatide a promising candidate for achieving and maintaining optimal blood sugar levels in patients with T2DM.
Clinical trials evaluating tirzepatide have demonstrated its efficacy in improving glycemic control, as evidenced by reductions in hemoglobin A1c (HbA1c) levels, fasting plasma glucose levels, and body weight. Additionally, tirzepatide has shown a favorable safety profile, Tirzepatide weight loss treatment is injected once a week to help you lose weight as part of a wider diet and exercise programme. It’s found under the brand name Mounjaro.
Tirzepatide is the first dual-action medication created in the drug classes of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. It works by mimicking these hormones to control blood sugar levels, but research shows it also induces weight loss.
Tirzepatide is one of the few medications licensed in the UK for weight loss
What class of drug is tirzepatide?
Tirzepatide’s drug class is both a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. GIP and GLP-1 are hormones that occur naturally in your body. Tirzepatide works by imitating these 2 hormones to lower your blood sugar levels and appetite.
You may hear tirzepatide being referred to as a dual receptor agonist. It is the first drug in this class of medications to be approved and released for type 2 diabetes and weight management. Mounjaro is the brand name for tirzepatide for weight loss
What is tirzepatide used for?
Tirzepatide works by reducing your appetite and slowing down the movement of food from the stomach to the small intestine. This process helps to leave you feeling fuller for longer, making it easier to reduce your calorie intake. For this reason, tirzepatide has been released as a medication for weight loss.
Tirzepatide is also approved for the treatment of type 2 diabetes. Tirzepatide lowers blood sugar levels by increasing the production of insulin and lowering the amount of sugar your liver makes.
Dosing Range 2.5mg–15mg weekly
Syringe Type Built-in dial with preset delivery
Injection Type Subcutaneous (once weekly)
Storage Refrigerate at 2–8°C. Use within 30 days once opened.
➡️ One pen = 2–12 weeks, depending on dose.
Inject once a week – same day and time each week
Do not shake or freeze. Use only if solution is clear.
DOSAGE CALCULATOR – TIRZEPATIDE WEEKLY PLANNER
TIDLIRA contains 10mg/ml. So:
- 0.25ml = 2.5mg
- 0.5ml = 5mg
- 0.75ml = 7.5mg
- 1.0ml = 10mg
- 1.5ml = 15mg
3–4 5.0mg 0.5ml Begin fat loss effect
5–6 7.5mg 0.75ml Increased insulin control
7–8 10.0mg 1.0ml Ideal for most users
9+ 12.5–15mg 1.25–1.5ml Max effective dose (if tolerated)
✅ Tirzepatide works best when increased gradually to reduce nausea and digestive
upset.
